Icon

ZOSYN (nda050684)- (EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL,EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL,EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL,EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL)

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM WYETH PHARMS
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL,EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL,EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL,EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL
Yes No
2023-Apr-14 Expired
None None
None No
ZOSYN is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of:  Intra-abdominal infections in adult and pediatric patients 2 months of age and older  Nosocomial pneumonia in adult and pediatric patients 2 months of age and older  Skin and skin structure infections in adults  Female pelvic infections in adults  Community-acquired pneumonia in adults.
19 0 18
Total Other Developers None
Drugs with Suitability Yes
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL ** ** - - -
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL ** ** - - 10
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL ** ** - - -
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 17
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ***** ****** ******* ***** *** ******* ******* *********** ** **: *** ** ***, *** ** ***, *** ** ***, *** ** ***, *****, ***, **** **: *-*/*, *-* & *-*, ********* *******, ********* ******, ************, ********* ******, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** ********* **** ***** ****** ****** *** *********** ****** ******* *** *** ***** ******, ** **,***, *.*** *******, ****** *****, ***** (***) ***
****** ********* **** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ******** ******** ***** ************** **., ***. *********** **. ***, ******* ****, ******* ****., *****, ******, ***** (***) ***
****** ********* *** ** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ****** ****** ********* ******* ******* *********** ***, *.*.*.*., *********, ********, ******* ******, ***** (***) ***
****** ************ ******* ************ *********** ******* ******* *********** ******* ******* ********, *** ***, ***********, ************ ****, *********, ********* ******, ***** (***) ***
****** ************ ******* ************ *********** ******* ******* *********** **** ****** ********, ***/* & ***/**, *************, ***********, ************ ****,, *********, ********* ******, ***** (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** ****** ******** ***** ************** **., ***. *** *********** **. ***, ******* ****, ******* ****., *****, ******, ***** (***) ***
****** ********* **** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ********* *** ** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ******** ******** ***** ************** **., ***. *********** **. ***, ******* ****, ******* ****., *****, ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.